PE20252677A1 - Amidas de azolipiridina piridazinona como inhibidores de sos1 - Google Patents
Amidas de azolipiridina piridazinona como inhibidores de sos1Info
- Publication number
- PE20252677A1 PE20252677A1 PE2025001751A PE2025001751A PE20252677A1 PE 20252677 A1 PE20252677 A1 PE 20252677A1 PE 2025001751 A PE2025001751 A PE 2025001751A PE 2025001751 A PE2025001751 A PE 2025001751A PE 20252677 A1 PE20252677 A1 PE 20252677A1
- Authority
- PE
- Peru
- Prior art keywords
- independently
- azolipyridine
- pyridazinone
- amides
- cra
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se refiere a unos compuestos representados por la Formula I, o un solvato, estereoisomero o sal farmaceuticamente aceptable del mismo, donde Z1 y Z3 son, independientemente, N o CH; Z2 es N o CRa, y Z4 es CH; o Z2 es CRa, y Z4 es N; y Ra, R1, R3, R4, A2, es cada uno independientemente H, halogeno, entre otros; R2 es H, alquilo C1-C6 opcionalmente sustituido con uno o mas de deuterio, entre otros; A1 es alquilo C1-C6 sustituido con uno o mas sustituyentes seleccionados independientemente del grupo que consiste en deuterio, halogeno, entre otros; A3 es H, amino, entre otros. Asimismo, la presente invencion se refiere a una composicion farmaceutica que comprende dicho compuesto, o un solvato, estereoisomero o sal farmaceuticamente aceptable del mismo, como ingrediente activo. Dicha composicion permite la prevencion o el tratamiento de una enfermedad mediada por SOS1, como un cancer seleccionado entre cancer de pancreas, cancer de pulmon, entre otros; o una RASopatia, seleccionada entre neurofibromatosis tipo 1, sindrome de Noonan, entre otras.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20230020903 | 2023-02-16 | ||
| PCT/KR2024/095359 WO2024172632A1 (ko) | 2023-02-16 | 2024-02-16 | Sos1 억제제로서의 아졸릴피리딘 피리다지논 아미드 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20252677A1 true PE20252677A1 (es) | 2025-11-24 |
Family
ID=92420433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2025001751A PE20252677A1 (es) | 2023-02-16 | 2024-02-16 | Amidas de azolipiridina piridazinona como inhibidores de sos1 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4667464A1 (es) |
| KR (1) | KR20240127909A (es) |
| CN (1) | CN120712259A (es) |
| AU (1) | AU2024220775A1 (es) |
| CL (1) | CL2025002211A1 (es) |
| IL (1) | IL322640A (es) |
| MX (1) | MX2025009392A (es) |
| PE (1) | PE20252677A1 (es) |
| TW (1) | TW202448871A (es) |
| WO (1) | WO2024172632A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2004002050A1 (es) * | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
| JP5944503B2 (ja) * | 2011-07-27 | 2016-07-05 | エービー サイエンス | 選択的プロテインキナーゼ阻害剤 |
| RU2014147017A (ru) * | 2012-04-24 | 2016-06-10 | Чугаи Сейяку Кабусики Кайся | Производное бензамида |
| US20140073634A1 (en) * | 2012-08-24 | 2014-03-13 | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center | Heterocyclic modulators of hif activity for treatment of disease |
| MY208632A (en) * | 2017-12-21 | 2025-05-21 | Boehringer Ingelheim Int | Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors |
-
2024
- 2024-02-16 KR KR1020240022965A patent/KR20240127909A/ko active Pending
- 2024-02-16 TW TW113105550A patent/TW202448871A/zh unknown
- 2024-02-16 EP EP24757342.1A patent/EP4667464A1/en active Pending
- 2024-02-16 WO PCT/KR2024/095359 patent/WO2024172632A1/ko not_active Ceased
- 2024-02-16 IL IL322640A patent/IL322640A/en unknown
- 2024-02-16 CN CN202480013425.8A patent/CN120712259A/zh active Pending
- 2024-02-16 PE PE2025001751A patent/PE20252677A1/es unknown
- 2024-02-16 AU AU2024220775A patent/AU2024220775A1/en active Pending
-
2025
- 2025-07-24 CL CL2025002211A patent/CL2025002211A1/es unknown
- 2025-08-11 MX MX2025009392A patent/MX2025009392A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024172632A1 (ko) | 2024-08-22 |
| CL2025002211A1 (es) | 2025-10-03 |
| MX2025009392A (es) | 2025-09-02 |
| TW202448871A (zh) | 2024-12-16 |
| EP4667464A1 (en) | 2025-12-24 |
| AU2024220775A1 (en) | 2025-07-17 |
| KR20240127909A (ko) | 2024-08-23 |
| CN120712259A (zh) | 2025-09-26 |
| IL322640A (en) | 2025-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20252677A1 (es) | Amidas de azolipiridina piridazinona como inhibidores de sos1 | |
| PE20240879A1 (es) | Inhibidor sos1 y uso del mismo | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20251323A1 (es) | Compuestos triciclicos y sus usos | |
| CO2024017733A2 (es) | Inhibidores macrocíclicos de kras para el tratamiento de cáncer | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| PE20201256A1 (es) | Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas | |
| PE20220705A1 (es) | Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| CO6331462A2 (es) | Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa | |
| PE20210477A1 (es) | Derivado policiclico de carbamoilpiridona | |
| PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
| PE20250833A1 (es) | Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead | |
| MX2024012967A (es) | Derivados de piridina para el tratamiento de los trastornos psiquiatricos | |
| CL2023000418A1 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| TW200621694A (en) | Substituted n-sulfonylaminobenzyl-2-phenoxyacetamide compounds | |
| PE20232047A1 (es) | Quinolinas y azaquinolinas como inhibidores de cd38 | |
| PE20252162A1 (es) | Derivados de benzimidazol ciclico como inhibidores de cgas | |
| BR112013024497A2 (pt) | novo derivado de oxazolidinona e composição farmacêutica incluindo o mesmo | |
| PE20240776A1 (es) | Compuestos terapeuticos y procedimientos | |
| CL2023000200A1 (es) | Nuevo derivado de pirazol | |
| AR127255A1 (es) | NUEVOS DERIVADOS DE BENZODIAZEPINA COMO GABAA g1 PAM |